SEC 13F Intelligence

Managers / Q4 2023 · view latest →

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$132M
Q4 2023
Positions
35
Filings on Record
16
2019–present window
Filed
Feb 2, 2024
amendment (RESTATEMENT)

Summary

Bml Capital Management, LLC reported $132M in U.S.-listed holdings across 35 positions for Q4 2023.

The portfolio is heavily concentrated: Ishares Tr alone accounts for 20.5% of reported value.

Compared with Q3 2023, the fund opened 14 new positions and exited 5.

Portfolio Metrics

Turnover
+10.0%
vs prior filed quarter
Top-10 Concentration
+76.6%
share of reported value
Largest Position
+20.5%
Ishares Tr
New / Exited
14 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 41.8%ETP: 34.9%Other: 23.3%
  • Common Stock · 41.8% · $55M
  • ETP · 34.9% · $46M
  • Other · 23.3% · $31M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TOURMALINE BIO INCNEW+245.5K245.5K+$6M$6M
THESEUS PHARMACEUTICALS INCNEW+1.11M1.11M+$4M$4M
ANFABERCROMBIE & FITCH CONEW+900900+$3M$3M
DSGNDESIGN THERAPEUTICS INCNEW+1.03M1.03M+$3M$3M
CONNECT BIOPHARMA HLDGS LTDNEW+2.06M2.06M+$2M$2M
RENEO PHARMACEUTICALS INCNEW+1.31M1.31M+$2M$2M
WINGWINGSTOP INCNEW+900900+$1M$1M
GRPHGRAPHITE BIO INCNEW+447.4K447.4K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ISHARES TR0-3 MNTH TREASRY20.51%$27M270.0K
2SPDR SER TRBLOOMBERG 1-3 MO13.84%$18M200.0K
3AVIRATEA PHARMACEUTICALS INChistory →COM12.62%$17M5.46M
4CYTEIR THERAPEUTICS INCCOM7.48%$10M3.25M
5TOURMALINE BIO INCCOM4.87%$6M245.5K
6CLYMELIEM THERAPEUTICS INChistory →COM4.46%$6M2.18M
7AVROBIO INCCOM4.12%$5M4.00M
8THESEUS PHARMACEUTICALS INCCOM3.40%$4M1.11M
9ATHIRA PHARMA INCCOM2.68%$4M1.45M
10ADVMCHFADVERUM BIOTECHNOLOGIES INChistory →COM2.60%$3M4.55M
11ORMPORAMED PHARMACEUTICALS INChistory →COM NEW2.21%$3M1.26M
12DSGNDESIGN THERAPEUTICS INChistory →COM2.07%$3M1.03M
13CONNECT BIOPHARMA HLDGS LTDADS1.84%$2M2.06M
14RENEO PHARMACEUTICALS INCCOM1.59%$2M1.31M
15ASTCASTROTECH CORPhistory →COM1.42%$2M220.4K
16RAIN ONCOLOGY INCCOM1.23%$2M1.35M
17TOCAEURFORTE BIOSCIENCES INChistory →COM1.10%$1M1.76M
18VERRICA PHARMACEUTICALS INCCOM1.00%$1M180.0K
19ABIOEURARCA BIOPHARMA INCCOM0.91%$1M706.9K
20GRPHGRAPHITE BIO INCCOM0.89%$1M447.4K
21KNTEUSDKINNATE BIOPHARMA INCCOM0.84%$1M468.2K
22VTGNVISTAGEN THERAPEUTICS INCCOM0.58%$771,000150.0K
23MISTMILESTONE PHARMACEUTICALS INCOM0.56%$738,728442.4K
24LSTALISATA THERAPEUTICS INCCOM0.56%$736,660269.8K
25ELVNENLIVEN THERAPEUTICS INCCOM0.52%$692,00050.0K
26ACRSACLARIS THERAPEUTICS INCCOM0.52%$685,762653.1K
27NGNENEUROGENE INCCOM0.36%$478,02724.7K
28HOMOLOGY MEDICINES INCCOM0.34%$454,850748.1K
29CALCCALCIMEDICA INCCOM NEW0.32%$415,913145.4K
30NXTCEURNEXTCURE INCCOM0.26%$349,370306.5K
31TLISTALIS BIOMEDICAL CORPCOM NEW0.24%$318,43542.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.